Non Allergic Asthma — Patent Landscape

Aggregated US Orange Book patent estate across every approved drug for non allergic asthma. 140 active patents protecting 2 drugs from 2+ originators. First major cliff: 2026. Daily refresh.

2
Approved drugs
140
Active US patents
51/100
Avg vulnerability
$69M
Annual revenue covered

Originators in Non Allergic Asthma

Companies holding active patents on drugs approved for this indication. Click through to each company's full patent dashboard.

Teva Pharm 118 patents Merck & Co. 22 patents

Cliff calendar — next 15 years

Patent expiries per year across all drugs treating non allergic asthma. Each bar = one year. Y-axis scaled to peak year (30 patents).

3
26
1
27
30
31
1
32
24
34
15
35
8
36
1
38
22
39
28
40
7
41

Approved drugs ranked by patent estate

Drug Originator Active patents Avg vuln Revenue First cliff
Cutivate
FLUTICASONE PROPIONATE
 Teva Pharm 118 58 $69M 2026-08-26
Elocon
MOMETASONE FUROATE
 Merck & Co. 22 44 — 2026-11-29

Most attackable patents

Highest vulnerability scores in the indication — paragraph IV / IPR / design-around candidates.

Patent Drug Type Vuln Expiry
12083270 Cutivate method of use 81 2031-04-04
7500444 Cutivate other 80 2026-08-26
7500444 Cutivate other 80 2026-08-26
11554229 Cutivate method of use 70 2036-02-23
10195375 Cutivate other 68 2031-08-14
10195375 Cutivate other 68 2031-08-14
10195375 Cutivate other 68 2031-08-14
10195375 Cutivate other 68 2031-08-14
10195375 Cutivate other 68 2031-08-14
10195375 Cutivate other 68 2031-08-14

Strongest defences

Lowest vulnerability scores — pillars of the indication's IP fortress.

Patent Drug Type Vuln Expiry
12303635 Elocon composition of matter 0 2039-04-08
10406332 Elocon formulation 25 2034-03-13
8763222 Elocon formulation 31 2032-02-08
11679210 Elocon formulation 33 2038-09-03
10561672 Elocon formulation 33 2034-09-04
9937189 Elocon formulation 33 2034-09-04
9370483 Elocon formulation 33 2034-09-04
10376526 Elocon formulation 33 2034-09-04
11173259 Cutivate formulation 42 2040-07-06
11173259 Cutivate formulation 42 2040-07-06

Related